Health related quality of life (HRQOL) evaluated with the EORTC C30 questionnaire in first line therapy of elderly patients with chronic lymphocytic leukemia (CLL): Results of a phase III trial of the ...

Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann ...

Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic ...

Prediabetes and Associated Risk of Cardiovascular Events and Chronic Kidney Disease Among Adult Survivors of Childhood Cancer in the St Jude Lifetime Cohort We report a phase I study of cemiplimab for ...

The reality of a population who is aging at an accelerated rate makes it a priority to understand what happens in the body over time, on a molecular scale. The mTOR protein complex is known to be ...

“Our participation in Boston transformed our standing from a quiet innovator to a recognized problem-solver in the DDR space,” added Prof. Daugaard. “We have confirmed that our scientific rationale is ...